AU2003203146A1 - Use of glp-1 compound for treatment of critically ill patients - Google Patents

Use of glp-1 compound for treatment of critically ill patients

Info

Publication number
AU2003203146A1
AU2003203146A1 AU2003203146A AU2003203146A AU2003203146A1 AU 2003203146 A1 AU2003203146 A1 AU 2003203146A1 AU 2003203146 A AU2003203146 A AU 2003203146A AU 2003203146 A AU2003203146 A AU 2003203146A AU 2003203146 A1 AU2003203146 A1 AU 2003203146A1
Authority
AU
Australia
Prior art keywords
glp
compound
treatment
critically ill
ill patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003203146A
Inventor
Kristian Tage Hansen
Lotte Bjerre Knudsen
Johan Selmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2003203146A1 publication Critical patent/AU2003203146A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
AU2003203146A 2002-02-07 2003-01-31 Use of glp-1 compound for treatment of critically ill patients Abandoned AU2003203146A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200184 2002-02-07
DKPA200200184 2002-02-07
PCT/DK2003/000061 WO2003066084A1 (en) 2002-02-07 2003-01-31 Use of glp-1 compound for treatment of critically ill patients

Publications (1)

Publication Number Publication Date
AU2003203146A1 true AU2003203146A1 (en) 2003-09-02

Family

ID=27675514

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003203146A Abandoned AU2003203146A1 (en) 2002-02-07 2003-01-31 Use of glp-1 compound for treatment of critically ill patients

Country Status (2)

Country Link
AU (1) AU2003203146A1 (en)
WO (1) WO2003066084A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
BR122013025625B1 (en) 2008-10-17 2021-08-03 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL COMPOSITION, ITS USE AND METHOD OF PREPARATION OF THE SAME, KIT AND DEVICE
DK2498802T3 (en) * 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
MY159565A (en) 2009-11-13 2017-01-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
KR101983982B1 (en) 2011-08-29 2019-05-30 사노피-아벤티스 도이칠란트 게엠베하 Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
TWI780236B (en) 2013-02-04 2022-10-11 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104310A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
CN105960249B (en) 2014-01-09 2021-03-16 赛诺菲 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
BR112016013832A2 (en) 2014-01-09 2017-08-08 Sanofi Sa USE OF INSULIN ANALOG AND/OR DERIVATIVE, PHARMACEUTICAL FORMULATION AND PROCESS FOR THE PREPARATION OF THE SAME, KIT AND MEDICAL DEVICE
CN107206058A (en) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 Insulin glargine/lixisenatide fixed ratio preparaton
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
CN109762059B (en) * 2019-03-28 2021-01-12 清紫生物科技（深圳）有限公司 Novel glucagon analogue and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19530865A1 (en) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Active ingredient and agent for parenteral nutrition
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6469021B1 (en) * 1998-12-10 2002-10-22 Agouron Pharmaceuticals, Inc. Non-peptide antagonists of GLP-1 receptor and methods of use
WO2001085256A2 (en) * 2000-05-05 2001-11-15 Novo Nordisk A/S Critical illness neuropathy
SK1432004A3 (en) * 2001-10-01 2005-03-04 Eli Lilly And Company Medicament for reducing mortality and morbidity associated with critical illnesses

Also Published As

Publication number Publication date
WO2003066084A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
AU2003297621A1 (en) Medical devices for delivery of therapeutic agents
IL218909A0 (en) Treatment of diabetes
AU2003298043A1 (en) Surface treatment of medical device
AU2003279338A1 (en) Phenethanolamine derivatives for the treatment of respiratory diseases
AU2003210428A1 (en) Phenethanolamine derivatives for treatment of respiratory diseases
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2003203146A1 (en) Use of glp-1 compound for treatment of critically ill patients
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
AU2003279442A1 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2003234929A1 (en) Therapeutic agent for diabetes
AU2003256655A1 (en) Therapeutic compounds for treating dyslipidemic conditions
GB0201674D0 (en) Medical treatment
AU2003903387A0 (en) Combination therapy for treatment of neoplasia
ZA200405342B (en) The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus
AU2003256271A1 (en) Dialysis apparatus for treatment of vulnerable patients
LT1496918T (en) Use of sodium meta-arsenite for the treatment of tumours
AU2003296545A1 (en) Use of a trpm8-activating substance for the treatment of tumours
GB0212790D0 (en) Medicament for the treatment of diabetes
AU2003274649A1 (en) Diagnostic markers for therapeutic treatment
AU2003236787A1 (en) Use of alkylphosphocholines for the preventative treatment of protozoan diseases
AU2003258593A1 (en) Organophosphorous compounds for the treatment of helminthic infections
EP1177789A3 (en) Use of phytanic acid for the treatment of diabetes
EP1488800A4 (en) Agent for the treatment of protozoal diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase